Fetal sickle cell blood test makes progress

By LabPulse.com staff writers

June 17, 2019 -- A noninvasive cell-free DNA test used to screen fetuses for sickle cell disease was accurate in 21 out of 24 pregnant women studied, reported researchers from London at the European Society of Human Genetics (ESHG) meeting, held June 15-18 in Gothenburg, Sweden.

With the test, they successfully analyzed fetal samples taken from the maternal bloodstream of carriers of sickle cell disease, an inherited condition caused by a mutation in the hemoglobin gene. The researchers from Guy's and St. Thomas' National Health Service (NHS) Foundation Trust are working with Viapath in London and Nonacus in Birmingham to develop the test.

Testing was feasible at very early stages -- as early as eight weeks' gestation. Currently, fetal screening is done through chorionic villus sampling and amniocentesis. While the study was successful, the results were inconclusive in three cases, the group noted.

USPSTF questions blood lead screening in children, pregnant women
Blood testing for elevated lead levels is accurate, but there is not enough evidence to support the screening of asymptomatic pregnant women or asymptomatic...
Are commercial labs falling short in prenatal testing?
A study published April 3 in Genetics in Medicine found that commercial laboratories offering noninvasive prenatal screening (NIPS) for genetic...

Copyright © 2019 LabPulse.com

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.